D. J. Winston, F. Saliba, E. Blumberg, M. Abouljoud, J. B. Garcia-Diaz, J. A. Goss, L. Clough, R. Avery, A. P. Limaye, B. G. Ericzon, M. Navasa, R. I. Troisi, H. Chen, S. A. Villano, M. E. Uknis and for the 1263–301 Clinical Study Group Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial American Journal of Transplantation 12
Article first published online: 4 SEP 2012 | DOI: 10.1111/j.1600-6143.2012.04231.x
Despite maribavir's in vitro activity against cytomegalovirus, this multicenter randomized trial shows that oral maribavir dosed at 100 mg twice daily is not adequate for prevention of cytomegalovirus disease in cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.